Chronic inflammatory bowel disease is challenging to treat and carries a risk of complications, including the development of ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

The aim of this study was to assess the evolution of the need for surgery in Crohn’s disease during the last 25 years. Patients and Methods: The medical charts of 2573 patients were reviewed ...

Patients with severe bowel disease are set to benefit from a new drug that can eliminate their distressing symptoms in only ...

Guselkumab shows significant clinical and endoscopic benefits for adults with moderate to severe Crohn disease, offering a ...

AIMS To study fracture rates and risk factors for fractures in patients with Crohn's disease and ulcerative colitis. METHODS 998 self administered questionnaires were issued to members of the Danish ...

ncl.ac.uk The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and inflammatory response, fuelled by advances in both biotechnology and ...

Johnson & Johnson (J&J) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its ...

Janssen-Cilag Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC). The approval was granted on 16th May, 2025 to ...

Background: Psoriasis is a chronic inflammatory skin disease with a genetic predisposition and autoimmune ... Despite this, real-world data comparing guselkumab and risankizumab effectiveness and ...